OUP (Osage University Partners)
Venture capitalBala Cynwyd · Pre-Seed–Late Stage · 23 people tracked
Also known as Osage University Partners · OUP MANAGEMENT CO., LLC
Find your way into OUP (Osage University Partners)
5,045 people in our graph share verified history with the OUP (Osage University Partners) team — schools, employers, funds. One of them is your warm intro.
Investment thesis
OUP backs startups commercializing transformational deep-technology innovations that emerge from or are inspired by breakthrough scientific research. For over 15 years the firm has focused specifically on science-driven companies, drawing on a team of former scientists, consultants, and operators to help founders convert laboratory discoveries into market-ready products. It emphasizes expertise in university tech transfer ecosystems, working closely with TTOs, principal investigators, and students. As a long-term partner, OUP reserves meaningful capital for follow-on rounds and connects portfolio companies to a network of Fortune 500 leaders, strategic partners, founders, and other investors to support commercial growth.
Source: firm website, verified Sep 15, 2026.
Team · 23 people
from the firm's website & curated & public directories
What they invest in
from 88 of 125 portfolio companiesBiotech ×51Healthtech ×29AI & Machine Learning ×21Medical Devices ×18Deep Tech ×15Hardware ×11Digital Health ×8Enterprise Software ×8
HQs:United States×83Israel×2
Who they back
founder profiles across 63 portfolio companiesFounding team size:solo founder×302 founders×193 founders×84+ founders×6
Where their founders studiedfrom 55 founders with education data
University of California, Berkeley ×11Harvard University ×4Massachusetts Institute of Technology ×4Stanford University ×4The Johns Hopkins University School of Medicine ×3Caltech ×2Duke University ×2Indian Institute of Technology, Madras ×2
What their founders studiedfrom 58 founders with field-of-study data
Engineering ×22Computer Science ×13Life Sciences ×13Chemistry ×10Physics ×7Medicine ×5Business & Management ×3
Where their founders worked beforefrom 58 founders with career history
Carnegie Mellon University ×3Harvard Medical School ×3Juniper Networks ×3University of Washington ×3Broad Institute of MIT and Harvard ×2Columbia University in the City of New York ×2EMD Serono, Inc. ×2GNF ×2
42 founders hold a PhD · 5 hold an MBA (of 58 with degree data)
Investments · 125 tracked
founders shown can be your intro pathBy year:2026 · 12025 · 22024 · 12023 · 22022 · 32021 · 12020 · 32019 · 22018 · 22017 · 32016 · 32015 · 239 dated
Ambiq develops ultra-low-power semiconductor solutions and edge AI platforms for IoT and healthcare applications.
AI & Machine LearningIoTSemiconductorsAustin, US
Scott Hanson(Executive Officer, Director)inDennis Sylvester(Director)inFumihide Esaka(CEO)inScott Goodwin(Executive Officer)inJoseph A. Tautges(Director)Paul Rolls(Executive Officer)
Co-investorsCisco InvestmentsConductive VenturesKleiner PerkinsMatter Venture PartnersMercury FundMichigan Capital Network+5 more
Beam Therapeutics develops gene-editing medicines, particularly base editors and precision genome editing technologies, to create lifelong cures for patients with serious genetic diseases.
BiotechDeep TechMedical DevicesCambridge, US
David R. Liu(Founder and Inventor)inJ. Keith Joung(Founder and Inventor)inFeng Zhang(Founder and Inventor)David R. Liu, Ph.D.(Founder and Inventor)J. Keith Joung, M.D., Ph.D.(Founder and Inventor)Feng Zhang, Ph.D.(Founder and Inventor)
Co-investorsARCH Venture PartnersDreamers VCEight Roads VenturesF-Prime CapitalForesite CapitalGV (Google Ventures)+1 more
Evolv Technologies provides artificial intelligence-powered screening systems for weapons detection at facilities including schools, hospitals, stadiums, and workplaces, delivered through a subscription model that combines proprietary sensor hardware, cloud-based software, and analytics dashboards with ongoing support services.
Waltham, US
Anil Chitkara(Executive Officer)Michael Ellenbogen(Executive Officer, Director)Kevin O'Brien(Executive Officer)John Kedzierski(Chief Executive Officer, President, and Director)inGeorge C. Kutsor(Chief Financial Officer)Robert Marshall(Chief Revenue Officer)in
Co-investorsDCVC (Data Collective)Lux Capital
Guardant Health develops blood-based testing (liquid biopsy) for cancer detection and monitoring across all stages of the disease.
BiotechDigital HealthHealthtechMedical DevicesRedwood City, US
AmirAli Talasaz(Executive Officer, Director)inHelmy Eltoukhy(Executive Officer, Director)inMichael Wiley(Executive Officer)inMichael Bell(Chief Financial Officer)Darya Chudova(Chief Technology Officer)inCraig Eagle(Chief Medical Officer)in
Co-investors8VCAUTHENTIC VENTURESCota CapitalFelicis VenturesKhosla VenturesKnockout Capital+7 more
IonQ develops and operates quantum computers based on trapped-ion technology, selling access to its systems through major cloud platforms (AWS, Microsoft Azure, Google Cloud) as well as directly to customers, and manufactures specialized quantum computing hardware alongside complementary quantum networking, sensing, and security products.
Niccolo M. de Masi(Chairman, President and Chief Executive Officer)Inder M. Singh(Chief Financial Officer and Chief Operating Officer)Paul T. Dacier(Chief Administrative Officer, Chief Legal Officer and Corporate Secretary)Dean P. Acosta(Chief Corporate Affairs and Government Relations Officer)Scott F. Millard(Chief Business Officer)
Co-investorsCorrelation VenturesFPVManta Ray VenturesRuna CapitalSamsung Catalyst FundSilver Lake Partners+4 more
Kura Oncology is a company in the oncology/medtech sector that provides grant support for independent medical education programs designed to enhance healthcare professionals' ability to diagnose and treat patients in Kura Oncology's therapeutic areas of interest.
BiotechDigital HealthMedical DevicesLa Jolla, US
TROY WILSON(Executive Officer, Director)inPINGDA REN(Executive Officer)inYI LIU(Executive Officer)inTroy Wilson(Founder)inTroy E. Wilson(President and Chief Executive Officer, Chairman of the Board)inHEIDI HENSON(Executive Officer)in
Co-investorsARCH Venture PartnersAvoro Capital AdvisorsEcoR1 CapitalForesite CapitalNextech InvestARCH Venture
A Spanish-language blog that publishes articles on health and medicine topics, such as flu prevention and vaccination recommendations, for general readers.
BiotechMedia & EntertainmentAustin, US
Matthew Winkler(Director)Sinil Kim(Executive Officer)inPaul Lammers(Executive Officer, Director)inJon Irvin(Executive Officer)Casi DeYoung(Executive Officer)
BoardMichael Powell(Director)
Co-investorsNew Enterprise Associates (NEA)Pfizer Venture InvestmentsOrbiMed
Precision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).
BiotechDeep TechHealthtechDurham, US
DEREK JANTZ(Executive Officer, Director)inMATTHEW KANE(Executive Officer, Director)Jeff Smith(Co-founder)inDerek Jantz(Co-founder)inTODD MELBY(Executive Officer)inMichael Amoroso(President, Chief Executive Officer)in
Co-investorsage1Agent CapitalAliment CapitalBrace PharmaF-Prime CapitalOCV Partners+4 more
Prime Medicine develops one-time genetic therapies using Prime Editing, a gene editing technology developed in David R.
BiotechDeep TechHealthtechMedical Devices
Andrew Anzalone(Co-founder and Head of Platform)inDavid Liu(Co-founder)inAllan Reine(Chief Executive Officer)inMohammed Asmal(Chief Medical Officer)inAnn Lee(Chief Technical Officer)inSvetlana Makhni(Chief Financial Officer)in
Co-investorsARCH Venture PartnersGV (Google Ventures)Newpath PartnersF-Prime CapitalSamsara BioCapitalArrive
Q32 Bio is a biotechnology company developing therapies for autoimmune and inflammatory diseases, with a scientific focus on the complement system and immune regulation in conditions such as inflammation, autoimmunity and fibrosis.
BiotechHealthtech
Shelia Violette(Founder & Chief Scientific Officer)inMichael Holers(Co-founder)Jodie Morrison(Chief Executive Officer)inLee Kalowski(President & Chief Financial Officer)Maria Marzilli(Chief Business Officer)inDavid Appugliese(Senior Vice President, Head of People)in
Co-investorsAtlas VentureOrbiMedAgent CapitalCU Healthcare Innovation FundSanofi Ventures5AM Ventures+2 more
Sera Prognostics develops women's health diagnostics focused on pregnancy, including the PreTRM blood test that predicts an individual's risk of spontaneous preterm birth in singleton pregnancies and the LikeMine platform that compares pregnancy outcomes using U.S. pregnancy data.
BiotechDigital HealthFemTechHealthtechSalt Lake City, US
Douglas Fisher(Executive Officer)Jay Moyes(Executive Officer)inGregory C. Critchfield(Executive Officer, Director)inAndrew A. Sauter(Executive Officer)inZhenya Lindgardt(President and Chief Executive Officer)in
BoardMansoor Mirza(Director)
Co-investorsaMoonExcelestar VenturesUpStart VenturesVivo CapitalCatalyst Health VenturesDomain Associates
Spero Therapeutics is a clinical-stage biopharmaceutical company developing medicines for immune-mediated diseases, led by SP001, a third-generation anti-CD40L antibody targeting IgG4-related disease.
BiotechCambridge, US
Ankit Mahadevia(Executive Officer, Director)inStephen Garbacz(Executive Officer)inEsther Rajavelu(Director, President, Chief Executive Officer, Chief Financial Officer, Chief Business Officer and Treasurer)in
BoardJean-Francois Formela(Director)inReza Halse(Director)Casper Breum(Director)
Co-investorsHEALTHCARE ROYALTY PARTNERSMRL Ventures FundRA CapitalAlphabetAtlas VentureFidelity Investments
Veradermics is developing VDPHL01, an extended-release oral minoxidil tablet intended as a non-hormonal prescription treatment for pattern hair loss in women and men.
BiotechHealthtechWest Hartford, US
Reid Waldman(Chief Executive Officer and Board Member)inTim Durso(Chief Technical Officer)inDominic Carrano(Chief Financial Officer and Treasurer)inMark Neumann(Chief Commercial and Strategy Officer)John W. Childs(Director)Jane Grant-Kels(Director)
Co-investorsLongitude CapitalConnecticut InnovationsSR One Capital Managementabrdn plcInvusLifeSci Venture Partners
Vor Biopharma is a biopharmaceutical company.
BiotechCambridge, US
Nathan Jorgensen(Executive Officer)Amy Mendel(Executive Officer)Robert Ang(Executive Officer, Director)Jean-Paul Kress(President, Chief Executive Officer and Chairman of the Board)in
BoardKush Parmar(Director)inJoshua Resnick(Director)
Co-investors5AM VenturesRA CapitalPureTech Health
Eridu develops networking infrastructure optimized for artificial intelligence workloads.
AI & Machine LearningCloud ComputingDeep TechHardwareSaratoga, US
Drew Perkins(CEO and founder)inBrian Kinard(Executive Officer)in
BoardJagdeep Singh(Director)Dipender Saluja(Director)Wen Hsieh(Director)inChristian Gallagher(Director)
Co-investorsBosch VenturesCatapult VenturesMatter Venture PartnersSocratic PartnersZelda VenturesBlack Opal Ventures+13 more
Aerie Pharmaceuticals develops ophthalmic pharmaceutical products including Rocklatan and Rhopressa for glaucoma and ocular hypertension, and AR-15512 for dry eye disease.
BiotechHealthtechMedical DevicesBedminster, US
CASEY KOPCZYNSKI(Executive Officer)inVICENTE ANIDO(Executive Officer, Director)BRIAN LEVY(Executive Officer)RICHARD RUBINO(Executive Officer)THOMAS MITRO(Executive Officer)David Endicott(CEO of Alcon)in
Co-investorsAlta PartnersAvoro Capital AdvisorsForesite CapitalSofinnova Ventures
Agita Labs develops hardware security and computer architecture technology focused on secure computation and side-channel resistance techniques.
CybersecurityDeep TechHardwareAnn Arbor, US
Valeria Bertacco(Co-founder)Todd Austin(Co-founder)Amy Wirth(Chief Financial Officer)Lip-Bu Tan(Director)
Algorithmia offers an enterprise AI platform for developing, deploying, and governing machine learning models and AI applications, with tooling tailored to roles across data science, engineering, DevOps, and IT teams.
AI & Machine LearningDeveloper ToolsEnterprise SoftwareSeattle, US
Kenneth F. Daniel(Executive Officer, Director)Diego M. Oppenheimer(Executive Officer, Director)in
BoardTimothy Porter(Director)inAnna Patterson(Director)in
Co-investorsGradient VenturesMadrona Venture GroupNorwest Venture PartnersOsage University PartnersWork-Bench
Develops therapeutics targeting altered NAD metabolism in cancer, using IP licensed from Yale University.
BiotechNew Haven, US
Barbara Fox(Executive Officer, Director)Nicholas J Galli(Executive Officer, Director)Stanley Choy(Executive Officer)inRanjit Bindra(Director)in
BoardColleen Cuffaro(Director)inMatthew Cohen(Director)in
%20copy.jpg)
Co-investorsCanaan PartnersConnecticut InnovationsHighCape Capital
Antiva Biosciences develops a topical therapeutic for women with high-risk HPV infection and pre-cancerous cervical lesions, utilizing antiviral prodrug chemistry.
BiotechFemTechHealthtechMedical DevicesRedwood City, US
Karl Y. Hostetler(Executive Officer, Director)inGail Maderis(Director)inKristine Ball(President & CEO)inElaine Chien(Executive Officer)inSarah Walter(Executive Officer)inRaju Gadiraju(Executive Officer)in
Co-investorsAdjuvant CapitalBrace PharmaCanaan PartnersLumira VenturesMPM BioImpactSofinnova Ventures+3 more
BiotechEvanston, US
Joseph R. Moskal(Chief Scientific Officer)Torsten M. Madsen(Chief Marketing Officer)Ashish Khanna(Secretary & Chief Business Officer)Norbert G. Riedel(Chief Executive Officer)
BoardLiam Ratcliffe(Director)Terry P. Gould(Director)
Co-investorsBain Capital Life SciencesFrazier Life SciencesLatterell Venture PartnersLongitude CapitalAgent CapitalHBM Healthcare Investments+2 more
Arrakis Therapeutics develops RNA-targeted small-molecule (rSM) medicines, working independently and with partners to create drug candidates aimed at the root causes of disease.
AI & Machine LearningBiotechDeep TechHealthtechCambridge, US
Michael Gilman(Executive Officer, Director)inMark DeLong(CEO)inDavid Neafus(Executive Officer)inRussell C. Petter(Executive Officer)
BoardColleen Cuffaro(Director)inAlan E. Walts(Director)in
Co-investorsCanaan PartnersPfizer VenturesAdvent Life SciencesNextech InvestPfizer Venture InvestmentsvenBio Partners+1 more
Arsenal Biosciences is a clinical-stage company developing programmable cell therapies to treat solid tumors.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Ken Drazan(Founder)James Ahlers(Executive Officer)Irene Pleasure(Executive Officer)Margaret Nibbi(Executive Officer)
BoardValentin Barsan(Director)Sean Parker(Director)
Co-investorsARCH Venture PartnersHitachi VenturesKleiner PerkinsSoftBank Vision FundWestlake Village BioPartners
AssetWatch provides cloud-based asset monitoring software and sensor technology to help manufacturing and industrial facilities prevent unplanned equipment downtime.
Advanced ManufacturingEnterprise SoftwareIoTSaaSWesterville, US
William Zell(Executive Officer, Director)William Ruff(Executive Officer)inRobert Lee(Director)inTad Dritz(VP of Development)inJeff Haskett(COO)inBrian Graham(Executive Officer, Director)in
Co-investorsCerity Partners VenturesG2 Venture PartnersHarmonic Growth PartnersJobsOhio VenturesMonte Carlo CapitalTriangle Peak Partners+4 more
Biohaven is a biopharmaceutical company that discovers, develops, and commercializes treatments across immunology, obesity, neuroscience, and oncology, targeting rare and common diseases with limited treatment options.
BiotechHealthtech
Vlad Coric(Chairman & Chief Executive Officer)in
Co-investorsAisling CapitalAPERTURE Venture PartnersConnecticut InnovationsHBM Healthcare InvestmentsOrbiMed
Brimstone develops co-production processes to manufacture cement, steel, aluminum, and other critical minerals from a single feedstock in an integrated facility.
Advanced ManufacturingCircular EconomyCleantechConstruction TechNew MaterialsOakland, US
Cody Finke(CEO)inHugo LeandriinCody Finke, Ph.D.(Founder)in
Co-investorsAccelr8Breakthrough Energy VenturesCollaborative FundCreative Destruction Lab (CDL)DCVC (Data Collective)Fifth Wall+7 more
BiotechLafayette, US
Peter Emtage(Executive Officer)inGreg Giotta(Executive Officer)Brian Atwood(Executive Officer, Director, Promoter)
BoardFred Cohen(Executive Officer, Director, Promoter)Brook Byers(Director)inArie Belldegrun(Director)
Co-investorsKleiner PerkinsMission Bay Capital
Clarifai developed AI inference technology and compute orchestration software for running and optimizing machine learning models at scale.
AI & Machine LearningCloud ComputingData & InfrastructureNew York, US
Matthew Zeiler(Executive Officer, Director)in
BoardAlbert Wenger(Director)in
Co-investorsBright Pixel CapitalCorazon CapitalGV (Google Ventures)Lux CapitalMenlo VenturesNew Enterprise Associates (NEA)+12 more
Caidya is a contract research organization (CRO) that provides scientific, medical, and operational support for clinical development and cross-border clinical trials.
BiotechDigital HealthHealthtechMorrisville, US
Mark Ubert(Executive Officer)Jesse Watson(Director)Brian Carney(Director)Jeff L. Williams(Executive Officer, Director)Melissa Daniels(Director)Christopher K. Porter(Executive Officer)
Co-investorsCreathor VenturesHatteras Venture Partners
Corelight provides network detection and response (NDR) software that uses agentic triage to automatically consolidate security alerts into entity-centric cases with evidence-backed investigation summaries.
AI & Machine LearningCybersecurityEnterprise Software
Co-investorsAccelCisco InvestmentsDelta-v CapitalEnergy Impact PartnersFlucas VenturesH.I.G. Capital+6 more
Cyteir is a clinical-stage oncology company developing CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters.
BiotechHealthtechCambridge, US
Kevin Mills(Executive Officer, Director)inRonald Goldstein(Executive Officer)inDonald Corcoran(Executive Officer, Director)inMarkus Renschler(Director)in
BoardTimothy Romberger(Director)Barry Mills(Director)
Co-investorsDroia VenturesLightstone VenturesAlly Bridge GroupDe Novo VenturesJanus Henderson InvestorsNovo Holdings+3 more
DELFI Diagnostics develops FirstLook Lung, a blood-based laboratory test for lung cancer screening that identifies genome-wide alterations in individuals eligible for screening.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesBaltimore, US
Victor Velculescu(Founder and Board Director)inPeter Bach(Executive Officer)Jennifer Buechel(Executive Officer)Douglas Schenkel(Executive Officer)Nicholas Dracopoli(Executive Officer)inSusan Tousi(Chief Executive Officer)in
Co-investorsAV8 VenturesForesite CapitalIllumina VenturesInitiate Venture PartnersMenlo VenturesOpen Field Capital+5 more
Dracen Pharmaceuticals is a private drug developer working at the intersection of cancer metabolism and immuno-oncology, developing glutamine antagonists that inhibit tumor glutamine metabolism and remodel the tumor microenvironment.
BiotechHealthtechBaltimore, US
Robert Wild(Co-founder & Chief Scientific Officer)Thomas M. Estok(Chief Executive Officer, President and Treasurer)Drew Pardoll, M.D., Ph.D.(Director)
BoardJonathan Leff(Director)Robert Jackson(Director)
Co-investorsBiotech Investments S.R.ODeerfield Management Company
eFFECTOR Therapeutics was a clinical-stage biopharmaceutical company.
BiotechSolana Beach, US
Stephen F. Worland, Ph.D.(Executive Officer, Director)Alana McNulty(Executive Officer)in
BoardSimeon George(Director)Jonathan Root(Director)inKen Haas(Director)Laurence Lasky(Director)
Co-investorsAstellas Venture Management LLCMission Bay CapitalMission BiocapitalPfizer Venture InvestmentsUS Venture PartnersSofinnova Ventures
Biotechnology company using multiplex gene editing to develop genetically engineered porcine organs for human transplantation.
BiotechBrookline, US
Luhan Yang(President, Secretary and Treasurer)Geoff MacKay(Chief Executive Officer)
BoardGeorge M. Church(Director)
Co-investorsAlta PartnersARCH Venture PartnersCatalio Capital Management, LPKhosla Venturesb2ventureKendall Capital Partners+1 more
Elementary builds data observability tools that monitor data quality and reliability for modern data teams.
AI & Machine LearningData & InfrastructureDeveloper ToolsEnterprise SoftwareTel Aviv-Yafo, IL
Maayan Salom(Founder)inOr Avidov(Founder)in
Co-investorsModern TechnicalY CombinatorThreshold Ventures
Elementary Robotics develops machine vision inspection systems for industrial quality control and defect detection.
Advanced ManufacturingAI & Machine LearningRobotics
Arye Barnehama(Founder)
Co-investorsRiot VenturesThundermark CapitalFathom CapitalFika VenturesThreshold VenturesTiger Global Management+2 more
EnaChip develops integrated magnetic structures — thin, small inductors fabricated with semiconductor-compatible electroplating — for point-of-load power delivery in AI infrastructure, advanced packaging, chiplets, and edge systems.
Deep TechHardwareSemiconductorsWilmington, US
Trifon M Liakopoulos(Executive Officer, Director, Promoter)Mark Allen(Co-Founder & CTO)Mark Popovich(CEO)inMichael Cassidy(Director)Michael Poisel(Director)
BoardMICHAEL BURYCHKA(Director)in
Co-investorsAnzu PartnersBoston Seed Capital
Everactive develops ultra-low power, self-powered systems-on-chip (SoCs) for Ambient IoT devices that sense, process, and wirelessly transmit data using harvested environmental energy instead of batteries.
HardwareIoTSemiconductorsSan Jose, US
Benton Calhoun(Executive Officer, Director)inDavid Wentzloff(Executive Officer, Director)Brendan R Richardson(Executive Officer, Director)
BoardGeorge Kastendike(Director)Greg Papadopoulos(Director)inJack Busch(Director)
Co-investorsBlue Bear Capital PartnersNew Enterprise Associates (NEA)ABB Technology VenturesGE VenturesOsage University Partners
Seattle biotech that developed FDY-5301 for cardiac and skeletal muscle injury; ceased operations in February 2026.
BiotechSeattle, US
Mark Roth(Executive Officer, Director, Promoter)Brian Blackman(Executive Officer)Simon Tulloch(Executive Officer)Stephen Hill(Executive Officer, Director)
BoardPaulina Hill(Director)Steven Gillis(Executive Officer, Director, Promoter)in
Co-investorsARCH Venture PartnersPolaris Partners
Fortis Therapeutics develops therapeutic treatments based on technology licensed from UCSF, with a focus on oncology and other disease areas.
BiotechHealthtechMedical DevicesSan Diego, US
Marc Nasoff(Chief Scientific Officer)
BoardJay B. Lichter(Ph.D.)in
Co-investorsVivo CapitalLilly Asia VenturesOsage University PartnersAvalon BioVentures
Hack The Box provides hands-on training and simulation platforms for cybersecurity blue teams, including labs, courses, and incident response exercises designed to develop skills in SOC operations, digital forensics, and threat hunting.
CybersecurityDeveloper ToolsEdTechEnterprise Software
Co-investorsBrighteye VenturesMarathon Venture CapitalPaladin Capital Group
Clinical-stage genetic medicines company using human-derived AAV vectors and nuclease-free gene editing for rare diseases.
BiotechBedford, US
Siyamak Rasty(Executive Officer)Albert Seymour(Executive Officer)
BoardSteven Gillis(Director)Arthur Tzianabos(Executive Officer, Director)Kush Parmar(Director)inRichard Gregory(Director)
Co-investors5AM VenturesARCH Venture PartnersAlexandriaDeerfield Management CompanyHBM Healthcare InvestmentsMaverick Ventures+4 more
HYALEX Orthopaedics develops a synthetic cartilage platform for joint repair in orthopaedic surgery.
HealthtechMedical DevicesLexington, US
Carl Vause(Executive Officer, Director)inMira Sahney(Executive Officer, Director)inDavid Myung(Director)
BoardMichael Hawkins(Director)Wende Hutton(Director)inWilliam Harrington(Director)in
Co-investorsCanaan PartnersTreo Ventures, LlcJohnson & Johnson Innovation – JJDCOsage University Partners
BiotechSeattle, US
Carlos V. Paya(Executive Officer, Director)Ed Penhoet(Director)Stephen R. Brady(Executive Officer)Jan Henrik ter Meulen(Executive Officer)David Baltimore(Director)William Ringo(Director)
Co-investorsSanofi Ventures
Infinite Uptime builds PlantOS, a prescriptive AI platform for heavy manufacturing that reads mechanical and process-induced fault signatures to tell plant operators which equipment fault to fix, why, and by when.
Advanced ManufacturingAI & Machine LearningIoTMenlo Park, US
Raunak Bhinge(Executive Officer, Director)inJean-David Margulici(Executive Officer, Director)
Co-investorsAvataar Venture PartnersDorm RoomGiTV, Inc.Mayfield FundTDK VenturesTrifecta Capital Advisors+2 more
.jpeg){kind=logo}
Vertically-integrated machine learning platform for healthcare powering transition to value-based care with predictive analytics.
Co-investorsMindset VentureOsage University PartnersPolaris Partners
Kymeta develops flat-panel satellite antennas and connectivity terminals, including its u5 and u8 product lines, that switch between LEO and GEO networks for mobile land and maritime use.
Defense TechHardwareSpace TechRedmond, US
Marc Stolzman(Executive Officer)inBill Marks(Executive Officer)Keith Cochran(Executive Officer)inManny Mora(President and CEO)inAnne(Chief Financial Officer)inRyan(Chief Scientist)in
Co-investorsLux CapitalManta Ray VenturesTectonic VenturesOsage University Partners
Global leader in silicon photonics, first to achieve direct 'fiber to the chip' integration on CMOS.
Carlsbad, US
Eli Yablonovitch(Director)Greg Young(Executive Officer, Director)inTom Foody(Executive Officer)
BoardAndy Rappaport(Director)Rohini Chakravarthy(Director)inForest Baskett(Director)
Co-investorsAugust CapitalCisco InvestmentsTEL Venture Capital, Inc.
MC10 developed conformal BioStamp wearable sensors and clinical analytics for physiological data capture in clinical research.
BiotechDigital HealthHealthtechMedical DevicesLexington, US
John Rogers(Director)David Icke(Executive Officer, Director)Alice Sansone(Executive Officer)Steven N. Tannenbaum(Executive Officer)Scott D. Pomerantz(Executive Officer, Director)
BoardMarc Singer(Director)in
Co-investorsBraemar Energy VenturesMitsui Global InvestmentWindham Capital PartnersAberdare VenturesNorth Bridge Venture Partners
Menlo Security provides a browser security platform that protects both human users and AI agents through a hybrid architecture combining local security controls with cloud-based threat protection.
AI & Machine LearningCybersecurityEnterprise SoftwareMountain View, US
Amir Ben-Efraim(Founder)inPoornima DeBolle(Founder)in
Co-investorsBaruch Future VenturesEngineering CapitalJuniperoGeneral CatalystJP Morgan ChaseNeuberger Berman+1 more
.png)
Metalenz develops metasurface optics technology for optical sensing in consumer and industrial devices.
Deep TechHardwareSemiconductorsStoneham, US
Federico Capasso(Director)Rob Devlin(Founder)in
BoardXuhui Shao(Director)in
Co-investorsBantam GroupBraemar Energy VenturesFoothill VenturesGlobal BrainIntel CapitalM Ventures+7 more
Mobia Medical (formerly MicroTransponder) develops Vivistim Paired VNS Therapy, an FDA-approved vagus nerve stimulation treatment for chronic ischemic stroke survivors with moderate to severe upper extremity impairment.
HealthtechMedical Devices
Jordan Curnes(Co-Founder)in
Co-investorsGreen Park & Golf VenturesUS Venture Partners
Neuros Medical develops the Altius Direct Electrical Nerve Stimulation System, an FDA-approved implantable device that delivers patient-controlled electrical stimulation to treat chronic post-amputation pain in adult lower limb amputees.
BiotechHealthtechMedical DevicesAliso Viejo, US
David Veino(President and CEO)Zach Stassen(Chief Financial Officer)Robert J. Centa(Chief Financial Officer)Jon J. Snyder(Director, President, Secretary and CEO)in
BoardJoyce Erony(Director)inWilliam Harrington(Director)
Co-investorsAmzak HealthAPERTURE Venture PartnersCWRU Technology VenturesiSelect FundJobsOhio VenturesJumpstart Ventures+6 more
Nocion Therapeutics develops small molecule charged sodium channel blockers (nocions) designed to silence overactive sensory nerves.
BiotechHealthtechMedical DevicesWatertown, US
MATTHEW FRANKEL(Executive Officer)inPETER COUROSSI(Executive Officer)RICHARD BATYCKY(Executive Officer, Director)JAMES ELLIS(Executive Officer)MICHAEL LIPP(Executive Officer)inCHRISTOPHER SILBER(Executive Officer)in
Co-investorsCanaan PartnersF-Prime CapitalMission BiocapitalMonograph Capital PartnersOsage University Partners
Opsys develops solid-state scanning LiDAR sensors with no moving parts, using VCSEL and SPAD chip technology for autonomous driving and industrial applications.
AI & Machine LearningDeep TechHardwareRoboticsIsrael, IL
Co-investors83NorthSaban VenturesTransLink CapitalOsage University Partners
Overland AI develops ground autonomy solutions for military vehicles and land operations, enabling autonomous mobility without human operators.
AI & Machine LearningDefense TechRoboticsSeattle, US
Byron Boots(Co-Founder & CEO)inStephanie Bonk(Co-Founder & President)inGreg Okopal(Co-Founder & COO)inJonathan Fink(Executive Officer)
BoardChristopher Morales(Director)
Co-investors8VCAscend Venture CapitalPoint72 VenturesVoyager CapitalCubit CapitalShasta Ventures+3 more
Picwell operates ALEX, a benefits decision-support platform that combines plan recommendations, enrollment, benefits administration, and year-round guidance for employees.
HR TechInsurTechSaaSPhiladelphia, US
Thomas Baker(Executive Officer, Director)Jonathan Thompson Kolstad(Executive Officer, Director)Robert James Town(Executive Officer, Director)Jay Silverstein(Executive Officer, Director)inAnirudh Vemprala(Executive Officer, Director)
BoardKevin Hill(Director)
Co-investorsBlue Venture FundsMassMutual VenturesOsage University Partners
HealthtechSan Francisco, US
Matthew F. Krummel, Ph.D.(Director)Steven P. James(Executive Officer, Director, Promoter)inLeon Chen, Ph.D.(Director)Carol Gallagher(Director)inJoshua Resnick, M.D.(Director)
BoardMichael Powell(Director)
Co-investorsMission Bay CapitalMission BiocapitalNew Enterprise Associates (NEA)Sofinnova VenturesOrbiMedSofinnova Venture Partners
PMV Pharma develops precision oncology therapies that target and structurally correct mutated p53 proteins to restore their tumor-suppressing function.
BiotechHealthtechCranbury, US
David H. Mack, Ph.D.(Founder)inDavid Mack(Executive Officer, Director)Arnold Levine(Director)
BoardPeter Thompson(Director)inSteve Winick(Director)Arnold Oronsky(Director)
Co-investorsAvoro Capital AdvisorsNextech InvestRA CapitalOrbiMedOsage University Partners
Precede Biosciences develops a blood-based diagnostic platform that profiles gene expression from cell-free DNA to reveal disease biology at the transcriptional level for drug developers and clinical trials.
AI & Machine LearningBiotechDigital HealthBoston, US
Rehan Verjee(Co-Founder, Chief Executive Officer, Board Director)inSylvan Baca(Co-Founder; Assistant Professor of Medicine, Dana-Farber Cancer Institute)inToni Choueiri(Co-Founder; Director, Lank Center for GU Oncology, Dana-Farber Cancer Institute)Matthew Freedman(Co-Founder; Professor of Medicine, Dana-Farber Cancer Institute)
Co-investorsIllumina Ventures5AM VenturesLilly Asia VenturesOsage University Partners
Quantum Circuits develops superconducting quantum computers using dual-rail qubits with built-in error detection, designed to accelerate the path to fault-tolerant quantum computing.
Advanced ManufacturingDeep TechHardwareQuantum ComputingMadison, US
Rob Schoelkopf(Sterling Professor, Founder)inLuigi FrunzioRay Smetsin
Co-investorsARCH Venture PartnersCanaan PartnersConnecticut InnovationsF-Prime CapitalFitz Gate VenturesTribeca Venture Partners+1 more
Quintessent develops optical connectivity solutions to address chip-to-chip communication bottlenecks in large-scale computing and AI systems.
AI & Machine LearningCloud ComputingDeep TechHardwareSemiconductorsSanta Barbara, US
Alan Liu(CEO, Co-Founder & Board Member)inBrian Koch(VP of Engineering & Co-Founder)inJohn Bowers(Chairman of the Board & Co-Founder)
Co-investorsEntrada VenturesFoothill VenturesM VenturesSierra Ventures
San Diego biopharmaceutical company developing GPCR-targeted immune-inflammatory drugs; acquired by Celgene for ~$7.2B in 2015.
BiotechSan Diego, US
Marcus Boehm(Executive Officer)inRobert Peach(Executive Officer)inRaymond Stevens(Director)inFaheem Hasnain(Executive Officer, Director)inJames Schmidt(Executive Officer)inChrysa Mineo(Executive Officer)in
Co-investorsARCH Venture PartnersVenrock
ReCode develops mRNA and gene correction therapeutics for genetic diseases, using proprietary lipid nanoparticle technology to deliver treatments to specific organs.
AI & Machine LearningBiotechHealthtechMedical DevicesMenlo Park, US
Dr. Daniel J. SiegwartArthur E Johnson(Executive Officer, Director)
Co-investorsAju IB Invesment CorporationEcoR1 CapitalEvolution VC PartnersMPM BioImpactOrbiMedPfizer Venture Investments+6 more
Redona Therapeutics is a drug discovery company co-founded by Harvard Medical School investigators focused on novel areas of biology.
AI & Machine LearningBiotechBoston, US
George Daley(Co-founder)Richard Gregory(Co-founder)Frank Slack(Co-founder)Piotr Sliz(Co-founder)inKazumi Shiosaki(President & CEO)in
Co-investorsAstellas Venture Management LLCSofinnova Partners
BiotechLexington, US
Victoria M. Richon(Executive Officer, Director)in
BoardCameron Wheeler(Director)Jonathan Root(Director)Laurence Lasky(Director)
Co-investorsAvego BioScience CapitalPeregrine VenturesAbbVieDeerfield Management CompanyNovartis Venture FundThe Column Group
Sana is a biotech company developing engineered cell medicines, including gene therapies for gene modification and delivery, cell replacement therapies using stem cell biology, and manufacturing solutions to improve patient access to these treatments.
BiotechHealthtechMedical DevicesSeattle, US
Richard Mulligan(Director)inHans Bishop(Director)Steve Harr(President and Chief Executive Officer)James J. MacDonald(Executive Officer)Nathan Hardy(Executive Officer)
.jpg?itok=YnNGtnt9)
BoardGeoffrey von Maltzahn(Director)in
Co-investorsAmerican Family VenturesARCH Venture PartnersF-Prime CapitalFlagship PioneeringInnovating CapitalJDRF T1D Fund+1 more
Satsuma Pharmaceuticals develops therapeutics for the acute treatment of migraine, including an approved dihydroergotamine nasal powder product (Atzumi/STS101).
BiotechHealthtechMedical DevicesSouth San Francisco, US
John Kollins(Executive Officer, Director)Tadayoshi Iwashima(Executive Officer)Thomas B. King(President and Board Director)inRob Janosky(Chief Commercial Officer)Tom O'Neil(Chief Financial Officer)inDavid Prichard(Chief Operating Officer)
Co-investorsVivo CapitalLumira VenturesOsage University PartnersRA CapitalRed Tree VentureSBI Investment
SiFive develops processor IP based on the open-standard RISC-V instruction set architecture, offering customizable and scalable chip designs.
Deep TechHardwareSemiconductorsSan Francisco, US
Yunsup Lee(Executive Officer, Director)inKrste Asanovic(Director)inAndrew WatermaninStefan A Dyckerhoff(Executive Officer, Director)inNaveed Sherwani(Executive Officer)inPatrick Little(CEO)in
Co-investorsBerkeley SkyDeck FundCoatue ManagementIntel CapitalProsperity7 VenturesQualcomm VenturesAtreides Management+6 more
Snowcap Compute develops superconducting computing platforms using Josephson Junctions to replace semiconductor transistors, delivering orders-of-magnitude greater energy efficiency for AI and high-performance computing workloads.
AI & Machine LearningDeep TechSemiconductorsSan Francisco, US
Anna Herr(Executive Officer)inQuentin Herr(Executive Officer)inMichael Shamus Lafferty(Executive Officer, Director)
BoardPat Gelsinger(Director)inRichard Hyman(Director)
Co-investorsPlayground GlobalCambium CapitalPage One Ventures
Sonoma Biotherapeutics develops engineered regulatory T cell therapies to treat autoimmune and inflammatory diseases.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Jeffrey Bluestone(Executive Officer, Director, Promoter)in
BoardFan Yu(Director)Maggie Wilderotter(Director)Toni Hoover(Director)Terry Rosen(Director)Richard Klausner(Director)
Co-investors8VCARCH Venture PartnersFrazier Life SciencesJDRF T1D FundLAVLifeforce Capital+1 more
StreetLight provides big data analytics for transportation planning and infrastructure investment decisions.
Climate TechData & InfrastructureGovTechLogistics & Supply ChainMobility & TransportationSan Francisco, US
Paul Friedman(Founder, Chief Technology Officer)inLaura Schewel(Executive Officer, Director, Promoter)in
BoardBill Perry(Director)Scott Pinizzotto(Director)Marc Singer(Director)inDarlene Mann(Director)
Co-investorsACTIVATE CAPITAL PARTNERS
Tessera provides a multi-agent AI platform for enterprise system modernization, automating processes across ERP, CRM, HCM, and finance systems with governed execution.
AI & Machine LearningEnterprise SoftwareSaaS
Kabir Nagrecha(Chief Executive Officer)inMing Chang(Chief Operating Officer)inAnirudh Sriram(Chief Technology Officer)inPrakash Gupta(Chief Revenue Officer)in
Co-investorsAndreessen HorowitzClear VenturesFoundation CapitalMyriad Venture PartnersOsage University Partners
BiotechSan Diego, US
Alain Baron(Executive Officer, Director)JeenJoo Kang(Director)Robert Tjian(Director)Marcus Boehm(Executive Officer)
BoardAndrew Schwab(Director)in
Co-investors5AM VenturesAvego BioScience CapitalNew Enterprise Associates (NEA)Sanofi VenturesThe Column GroupAbingworth+3 more
Trellis Air develops technology aimed at drying air using less energy.
CleantechClimate TechEnergySomerville, US
Russ Wilcox(Executive Officer, Director)
BoardCraig Shapiro(Director)
Co-investorsWorkshop Venture PartnersFounder Collective
Trulite Health builds Truity, a health optimization platform that delivers clinical, social, and behavioral decision support and patient-facing nudges to providers and care teams at the point of care.
Digital HealthHealthtechSaaSTempe, US
Alan C. Roga(Executive Officer, Director)inJohn Barravecchia(Executive Officer)inShaung Liu(Executive Officer)in
BoardCaleb DesRosiers(Director)
Co-investorsOsage Venture PartnersService Provider CapitalInflect Health
.png)
Arcadia (urjanet.com) offers a platform that unifies utility bill and interval data, tariff and energy rate calculations, and solar and storage analysis into energy data and analytics.
CleantechClimate TechData & InfrastructureEnergyAtlanta, US
SANJOY MALIK(Executive Officer, Director)in
BoardPETER KIGHT(Director)inSTEVE FREDRICK(Director)inSIG MOSLEY(Director)DAVID RATCLIFFE(Director)
Co-investorsCorrelation VenturesGrotech VenturesOak HC/FTCommerce Ventures
Verdox develops an electrochemical carbon capture system that uses electrical energy alone to capture and release CO₂ from both industrial point sources and ambient air.
CleantechClimate TechDeep Tech
Co-investorsAzolla VenturesBreakthrough Energy VenturesLOWERCARBONLowercarbon CapitalPrime Impact Fund
Verve Motion develops the SafeLift exosuit, a wearable device designed to reduce workplace injuries and increase productivity for physically demanding jobs.
Future of WorkHardwareLogistics & Supply ChainRobotics
Ignacio Galiana(Founder)in
Co-investorsConstruct CapitalCybernetix VenturesFounder CollectivePillar VCSafar Partners
Virtue AI offers an enterprise AI security platform that applies real-time guardrails, red-teaming, and compliance controls to AI models and agentic systems.
AI & Machine LearningCybersecurityEnterprise SoftwareSan Francisco, US
Sanmi Koyejo(Founder & Chief AI Officer)inBo Li(Founder & CEO)inDawn Song(Founder & Board Director)inCarlos Guestrin(Founder & Chief Scientist)in
Co-investorsWalden Catalyst
Xscape Photonics develops custom silicon photonics solutions aimed at solving bandwidth bottlenecks in AI compute clusters.
AI & Machine LearningDeep TechSemiconductorsFort Lee, US
Alexander Gaeta(Executive Officer, Director)inVivek Raghunathan(Executive Officer, Director)inYoshitomo Okawachi(Executive Officer)Alexander Kash(Executive Officer, Director)
BoardJames Scapa(Director)
Co-investorsCisco InvestmentsAdditionFathomFathom FundIAG Capital PartnersLifeX Ventures+1 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Aerovate TherapeuticsAGTCArtizan BiosciencesAtsena TherapeuticsAvid RadiopharmaceuticalsBioAgeBlade TherapeuticsBody LabsCapella BioscienceCardioxyl PharmaceuticalsCartesiaCensysChroma MedicineCleave TherapeuticsCoho TherapeuticsDICE TherapeuticsE-scape BioEinblickEmbodiedExostellarGraphite Bio, Inc.HiddenWeightsIconic TherapeuticsInterius BioTherapeuticsKolltan PharmaceuticalsLandos BiopharmaLunaDNAMediSix TherapeuticsMillendo TherapeuticsModis TherapeuticsNeurosNormunityNuMatOtonomyPalladio BiosciencesParacosmPerceptive AutomataResolv TechnologySeismosSelecta BiosciencesSynthorxTangent Medical TechnologiesVanqua Bio
Exits · 25
15 IPOs · 10 acquisitions · showing 19AmbiqNYSE: AMBQBeam TherapeuticsNASDAQ: BEAMEvolv TechnologiesNASDAQ: EVLVGuardant HealthNASDAQ: GHIonQNYSE: IONQKura OncologyNASDAQ: KURAMirna TherapeuticsOTC: SYBXPrecision BioSciencesNASDAQ: DTILPrime MedicineNASDAQ: PRMEQ32 BioNASDAQ: QTTBSera PrognosticsNASDAQ: SERASpero TherapeuticsNASDAQ: SPROVeradermicsNYSE: MANEVor BiopharmaNASDAQ: VORAerovate Therapeuticsacq. by Jade BiosciencesMC10acq. by MedidataMillendo Therapeuticsacq. by Tempest TherapeuticsModis Therapeuticsacq. by ZogenixSynthorxacq. by Sanofi
Portfolio news
latest coverage across their companiesEvolv Technologies · investing.com · Sep 3, 2026
Vor Biopharma · defenseworld.net · Sep 3, 2026
Prime Medicine · biospace.com · Sep 3, 2026
Sera Prognostics · news.alphastreet.com · Aug 20, 2026
Spero Therapeutics · marketbeat.com · Aug 18, 2026
KenSci · chiefhealthcareexecutive.com · Aug 17, 2026
Ribon Therapeutics · geekwire.com · Aug 14, 2026
Frequently asked questions
- How many investments has OUP (Osage University Partners) made?
- OUP (Osage University Partners) has 125 tracked investments, 25 of which have exited, including 3 dated in the last 24 months.
- What stage does OUP (Osage University Partners) invest at?
- OUP (Osage University Partners) invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What is OUP (Osage University Partners)'s typical check size?
- OUP (Osage University Partners) typically writes checks of $1M – $20M.
- What sectors does OUP (Osage University Partners) focus on?
- OUP (Osage University Partners) focuses on AI & Machine Learning, Biotech, Cleantech, Climate Tech, Cloud Computing, Cybersecurity, Deep Tech, Digital Health, Energy, Enterprise Software, Hardware, Healthtech, Medical Devices, New Materials, Quantum Computing, SaaS, Sector Agnostic, Semiconductors.
- Where is OUP (Osage University Partners) located?
- OUP (Osage University Partners) is headquartered in Bala Cynwyd, US.
- Does OUP (Osage University Partners) lead rounds?
- Yes, OUP (Osage University Partners) leads investment rounds.
- Who does OUP (Osage University Partners) co-invest with?
- OUP (Osage University Partners) most often shares deals with ARCH Venture Partners, F-Prime Capital, Canaan Partners, among 237 tracked co-investors.
Media · Podcasts & interviews
featuring the teamUniversity Spinouts and Deep Tech Investing | Marc Singer | Osage University Partners (OUP)
Deep Tech Leaders · Marc Singer
Ventures #15 w/ Matt Cohen - Managing Partner @ Osage University Partners (OUP) | BIOS
BIOS · Matt Cohen
Founder's Equity: Formation, Dilution, Industry Averages - Manny Stockman, Osage University Partners
UCLA TDG · Manny Stockman
Marc Singer, John Lee (Osage University Partners)
Marc Singer · vimeo.com
Advisory Boards in Academic Innovation: Three University Models
Osage University Partners
SBIR/STTR Reauthorization: Tips and Tricks for Navigating New Funding Opportunities
Osage University Partners
Images
Co-investors · 47
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.
5AM Ventures is a life science venture capital firm founded in 2002 that invests primarily in private therapeutic companies, with a focus on biopharmaceuticals, drug delivery technologies, and life science instruments.
Deerfield Management is a healthcare-focused investment firm that supports companies across the healthcare ecosystem through flexible funding, market intelligence, and philanthropic initiatives.
MPM BioImpact combines 30+ years of biotech venture capital expertise with impact investing and public market experience, managing early-stage venture funds, private/public impact funds, and a public equities fund focused on transforming patient outcomes.
Agent Capital is a healthcare venture capital firm that invests in novel, differentiated therapeutics and treatments addressing unmet patient needs across all stages of development.
Lux Capital is a venture capital firm that backs founders building transformative deep technologies, having been among the first investors in category-defining companies across AI, robotics, biotech, defense, and infrastructure.
US Venture Partners (USVP) is an early-stage venture capital firm investing in information technology and healthcare companies, with four decades of investing experience.
The Column Group (TCG) is a venture capital firm focused on building and backing biotechnology companies, applying an edge-to-edge investment model centered on company formation with capacity for long-term private and public capital support.
Nextech Invest is a Zurich-based investment firm focused on emerging biotechnology companies, backing transformative cancer medicines and precision medicine advances worldwide.
▶35 more co-investors
Breakthrough Energy VenturesDomain AssociatesHatteras Venture PartnersRiverVest Venture PartnersBraemar Energy VenturesAPERTURE Venture PartnersGeneral CatalystMadrona Venture GroupSierra VenturesG2 Venture PartnersMassMutual VenturesJAZZ Venture PartnersEQT Life SciencesEngineering CapitalVersant VenturesSR One Capital ManagementJohnson & Johnson Innovation – JJDCDeep Fork CapitalAberdare VenturesSignet Healthcare PartnersBessemer Venture PartnersPlug and Play VenturesCompany CapitalJavelin Venture PartnersAmerican Express Ventures (Amex)Gutbrain VenturesCalibrate VenturesVenture Guides Management, L.P.Pivotal Life SciencesNewfund CapitalAmara VCOmega FundsMedical Excellence CapitalChrysalixBrightCap Investment Advisor AD
Firms observed investing alongside OUP (Osage University Partners), from public investor directories. Shared companies are the overlap with OUP (Osage University Partners)'s recorded portfolio.
Similar investors
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Khosla Ventures is a venture capital firm founded by Vinod Khosla.
Everywhere Ventures is an early-stage venture firm, backed by a community of founders and operators as LPs, that writes early checks (including pre-seed) into startups across many sectors and geographies.
Alumni Ventures (AV) is a venture capital firm that co-invests alongside lead VCs in startups, backing founders with capital and access to a large investor and operator community.
BDC Fund Investments is the fund-of-funds arm of BDC Capital that acts as a limited partner in venture and growth capital funds backing technology-focused Canadian companies. It supports emerging and established fund managers to strengthen Canada's innovation ecosystem.